# Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

> **NCT00489918** · PHASE2 · COMPLETED · sponsor: **Zosano Pharma Corporation** · enrollment: 165 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** teriparatide
- **DRUG:** teriparatide

## Key facts

- **NCT ID:** NCT00489918
- **Lead sponsor:** Zosano Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-08
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489918, "Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00489918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*